Table 2.
Sample-based |
CMM (2stg) |
Joint model |
||||
---|---|---|---|---|---|---|
BM28 (n=52) | ||||||
μ+i | 0.668 | 0.232 | 0.630 | 0.236 | 1.481 | 0.501 |
Gleason | 0.666 | 0.601 | 0.683 | 0.561 | 0.592 | 0.558 |
Stage | 0.938 | 0.507 | 0.837 | 0.535 | 0.822 | 0.501 |
AMACR (n=203) | ||||||
πi | 0.827 | 0.358 | 1.284 | 0.539 | 1.778 | 0.586 |
μ+i | −1.132 | 0.464 | −0.554 | 0.402 | −0.488 | 0.389 |
μi | −0.736 | 0.457 | −1.008 | 0.458 | −2.372 | 0.728 |
Gleason | 1.237 | 0.418 | 1.177 | 0.42 | 1.025 | 0.513 |
Stage | 1.345 | 0.298 | 1.254 | 0.298 | 1.276 | 0.293 |
Prediction of patient PSA recurrence using tumor-wise protein expression estimates.